Cas 176787-42-1,cyclohexyl (4-nitrophenyl) carbonate

176787-42-1

Post Buying Request

Basic information

Product Name: cyclohexyl (4-nitrophenyl) carbonate
Synonyms: cyclohexyl (4-nitrophenyl) carbonate;cyclohexyl (4-nitrophenyl) carbonate(WXC03010)
CAS NO:176787-42-1
Molecular Formula: C₁₃H₁₅NO₅
Molecular Weight: 265.2619
EINECS: N/A
Product Categories: N/A
Mol File: 176787-42-1.mol
Article Data: 8

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: /
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: cyclohexyl (4-nitrophenyl) carbonate(CAS DataBase Reference)
NIST Chemistry Reference: cyclohexyl (4-nitrophenyl) carbonate(176787-42-1)
EPA Substance Registry System: cyclohexyl (4-nitrophenyl) carbonate(176787-42-1)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 176787-42-1(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

176787-42-1 Suppliers

Recommended suppliersmore

176787-42-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 176787-42-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,6,7,8 and 7 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 176787-42:
(8*1)+(7*7)+(6*6)+(5*7)+(4*8)+(3*7)+(2*4)+(1*2)=191
191 % 10 = 1
So 176787-42-1 is a valid CAS Registry Number.

176787-42-1Upstream product

176787-42-1Downstream Products

176787-42-1Relevant articles and documents

Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants

Nageswara Rao, Desaboini,Zephyr, Jacqueto,Henes, Mina,Chan, Elise T.,Matthew, Ashley N.,Hedger, Adam K.,Conway, Hasahn L.,Saeed, Mohsan,Newton, Alicia,Petropoulos, Christos J.,Huang, Wei,Kurt Yilmaz, Nese,Schiffer, Celia A.,Ali, Akbar

supporting information, p. 11972 - 11989 (2021/09/06)

The three pan-genotypic HCV NS3/4A protease inhibitors (PIs) currently in clinical use - grazoprevir, glecaprevir, and voxilaprevir - are quinoxaline-based P2-P4 macrocycles and thus exhibit similar resistance profiles. Using our quinoxaline-based P1-P3 m

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF

-

Paragraph 0099-00100, (2018/02/20)

The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosi

Bicyclic heterocycles as cannabinoid receptor modulators

-

Page/Page column 20, (2008/06/13)

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, n, and Z are described herein.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 176787-42-1